Does the media refer more to SGMO or LGVN?

In the previous week, Longeveron had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for Sangamo Therapeutics. Longeveron's average media sentiment score of 1.41 beat Sangamo Therapeutics' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LGVN or MDXH more profitable?

MDxHealth has a net margin of -33.46% compared to Longeveron's net margin of -1,977.59%. MDxHealth's return on equity of 0.00% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Longeveron -1,977.59% -223.19% -150.20% MDxHealth -33.46% N/A -24.25%

Is EDSA or LGVN more profitable?

Edesa Biotech has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Longeveron's return on equity of -223.19% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% Longeveron -1,977.59% -223.19% -150.20%

Does the media favor LGVN or CNTX?

In the previous week, Longeveron and Longeveron both had 3 articles in the media. Longeveron's average media sentiment score of 1.41 beat Context Therapeutics' score of -0.12 indicating that Longeveron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Longeveron (LGVN) Competitors

$1.73 -0.42 (-19.53%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$1.60 -0.13 (-7.28%)

As of 05:41 AM Eastern

Compare

LGVN vs. SGMO, BRNS, MDXH, EDSA, and CNTX

Should you buy Longeveron stock or one of its competitors? Longeveron's main competitors and comparable companies include Sangamo Therapeutics (SGMO), Barinthus Biotherapeutics (BRNS), MDxHealth (MDXH), Edesa Biotech (EDSA), and Context Therapeutics (CNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Longeveron compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Longeveron had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for Sangamo Therapeutics. Longeveron's average media sentiment score of 1.41 beat Sangamo Therapeutics' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Longeveron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market.

Longeveron has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Longeveron	$1.20M	4.60	-$22.70M	-$9.90	N/A

Sangamo Therapeutics has a net margin of -310.81% compared to Longeveron's net margin of -1,977.59%. Longeveron's return on equity of -223.19% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Longeveron	-1,977.59%	-223.19%	-150.20%

Sangamo Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Longeveron has a consensus target price of $80.00, suggesting a potential upside of 4,524.28%. Given Sangamo Therapeutics' higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Longeveron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Sangamo Therapeutics beats Longeveron on 8 of the 15 factors compared between the two stocks.

How does Longeveron compare to Barinthus Biotherapeutics?

Longeveron (NASDAQ:LGVN) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Longeveron has higher revenue and earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	4.60	-$22.70M	-$9.90	N/A
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A

Longeveron has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.37, indicating that its share price is 137% less volatile than the broader market.

Longeveron presently has a consensus target price of $80.00, indicating a potential upside of 4,524.28%. Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 440.47%. Given Longeveron's higher possible upside, equities research analysts plainly believe Longeveron is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Barinthus Biotherapeutics' return on equity of -59.15% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 7.4% of Longeveron shares are owned by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Longeveron had 3 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for Longeveron and 0 mentions for Barinthus Biotherapeutics. Longeveron's average media sentiment score of 1.41 beat Barinthus Biotherapeutics' score of 0.00 indicating that Longeveron is being referred to more favorably in the media.

Company	Overall Sentiment
Longeveron	Positive
Barinthus Biotherapeutics	Neutral

Summary

Longeveron beats Barinthus Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Longeveron compare to MDxHealth?

Longeveron (NASDAQ:LGVN) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

In the previous week, Longeveron had 2 more articles in the media than MDxHealth. MarketBeat recorded 3 mentions for Longeveron and 1 mentions for MDxHealth. Longeveron's average media sentiment score of 1.41 beat MDxHealth's score of 0.91 indicating that Longeveron is being referred to more favorably in the media.

Company	Overall Sentiment
Longeveron	Positive
MDxHealth	Positive

Longeveron currently has a consensus price target of $80.00, indicating a potential upside of 4,524.28%. MDxHealth has a consensus price target of $2.17, indicating a potential upside of 242.99%. Given Longeveron's higher possible upside, research analysts plainly believe Longeveron is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Longeveron has higher earnings, but lower revenue than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	4.60	-$22.70M	-$9.90	N/A
MDxHealth	$107.88M	0.29	-$33.52M	-$0.72	N/A

10.0% of Longeveron shares are held by institutional investors. 7.4% of Longeveron shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Longeveron has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

MDxHealth has a net margin of -33.46% compared to Longeveron's net margin of -1,977.59%. MDxHealth's return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
MDxHealth	-33.46%	N/A	-24.25%

Summary

Longeveron and MDxHealth tied by winning 8 of the 16 factors compared between the two stocks.

How does Longeveron compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Edesa Biotech has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Longeveron's return on equity of -223.19% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
Longeveron	-1,977.59%	-223.19%	-150.20%

Edesa Biotech has higher earnings, but lower revenue than Longeveron. Edesa Biotech is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
Longeveron	$1.20M	4.60	-$22.70M	-$9.90	N/A

Edesa Biotech has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market.

Edesa Biotech presently has a consensus target price of $5.00, indicating a potential upside of 88.68%. Longeveron has a consensus target price of $80.00, indicating a potential upside of 4,524.28%. Given Longeveron's higher probable upside, analysts clearly believe Longeveron is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Longeveron had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for Longeveron and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.79 beat Longeveron's score of 1.41 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Edesa Biotech	Very Positive
Longeveron	Positive

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Edesa Biotech beats Longeveron on 9 of the 14 factors compared between the two stocks.

How does Longeveron compare to Context Therapeutics?

Longeveron (NASDAQ:LGVN) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Longeveron has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

10.0% of Longeveron shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 7.4% of Longeveron shares are held by company insiders. Comparatively, 4.8% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Longeveron has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	4.60	-$22.70M	-$9.90	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

In the previous week, Longeveron and Longeveron both had 3 articles in the media. Longeveron's average media sentiment score of 1.41 beat Context Therapeutics' score of -0.12 indicating that Longeveron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Context Therapeutics' return on equity of -82.06% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
Context Therapeutics	N/A	-82.06%	-72.74%

Longeveron presently has a consensus target price of $80.00, suggesting a potential upside of 4,524.28%. Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 2,312.62%. Given Longeveron's higher probable upside, analysts plainly believe Longeveron is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Context Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Context Therapeutics beats Longeveron on 8 of the 13 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGVN vs. The Competition

Export

Metric	Longeveron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.85M	$3.84B	$7.18B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	-0.17	10.30	215.33	19.57
Price / Sales	4.60	1,163.44	571.63	81.29
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	0.70	16.17	10.37	5.92
Net Income	-$22.70M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-27.00%	-5.80%	-3.49%	-3.90%
1 Month Performance	-74.78%	-12.85%	-7.76%	-6.42%
1 Year Performance	-79.26%	3.02%	0.82%	-6.01%

Longeveron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGVN Longeveron	2.9308 of 5 stars	$1.73 -19.5%	$80.00 +4,524.3%	-78.4%	$6.85M	$1.20M	N/A	38	Positive News Short Interest Decrease
SGMO Sangamo Therapeutics	0.718 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
BRNS Barinthus Biotherapeutics	1.7019 of 5 stars	$0.74 flat	$4.00 +440.5%	N/A	$30.23M	N/A	N/A	107
MDXH MDxHealth	2.9732 of 5 stars	$0.66 +9.3%	$2.17 +228.3%	-84.6%	$29.89M	$107.88M	N/A	364	High Trading Volume
EDSA Edesa Biotech	2.9175 of 5 stars	$2.85 -3.1%	$5.00 +75.4%	+5.6%	$28.34M	N/A	N/A	17	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGVN) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Longeveron (LGVN) Competitors

LGVN vs. SGMO, BRNS, MDXH, EDSA, and CNTX

How does Longeveron compare to Sangamo Therapeutics?

Summary

How does Longeveron compare to Barinthus Biotherapeutics?

Summary

How does Longeveron compare to MDxHealth?

Summary

How does Longeveron compare to Edesa Biotech?

Summary

How does Longeveron compare to Context Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Longeveron (LGVN) Competitors

LGVN vs. SGMO, BRNS, MDXH, EDSA, and CNTX

How does Longeveron compare to Sangamo Therapeutics?

Does the media refer more to SGMO or LGVN?

Which has more volatility and risk, SGMO or LGVN?

Which has better earnings & valuation, SGMO or LGVN?

Is SGMO or LGVN more profitable?

Do analysts recommend SGMO or LGVN?

Do institutionals & insiders have more ownership in SGMO or LGVN?

Summary

How does Longeveron compare to Barinthus Biotherapeutics?

Which has preferable earnings and valuation, LGVN or BRNS?

Which has more volatility and risk, LGVN or BRNS?

Do analysts rate LGVN or BRNS?

Is LGVN or BRNS more profitable?

Do institutionals and insiders believe in LGVN or BRNS?

Does the media prefer LGVN or BRNS?

Summary

How does Longeveron compare to MDxHealth?

Does the media prefer LGVN or MDXH?

Do analysts rate LGVN or MDXH?

Which has better earnings and valuation, LGVN or MDXH?

Do insiders & institutionals hold more shares of LGVN or MDXH?

Which has more volatility & risk, LGVN or MDXH?

Is LGVN or MDXH more profitable?

Summary

How does Longeveron compare to Edesa Biotech?

Is EDSA or LGVN more profitable?

Which has higher earnings & valuation, EDSA or LGVN?

Which has more risk and volatility, EDSA or LGVN?

Do analysts rate EDSA or LGVN?

Does the media refer more to EDSA or LGVN?

Do institutionals & insiders believe in EDSA or LGVN?

Summary

How does Longeveron compare to Context Therapeutics?

Which has more risk & volatility, LGVN or CNTX?

Do institutionals and insiders believe in LGVN or CNTX?

Which has better earnings & valuation, LGVN or CNTX?

Does the media favor LGVN or CNTX?

Is LGVN or CNTX more profitable?

Do analysts rate LGVN or CNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools